INNOVANCE® VWF Ac Assay: Setting a New Standard in Automated VWF Activity Determination

An innovative new assay is available for the quantitative determination of von Willebrand factor activity—the INNOVANCE® VWF Ac Assay*. The assay employs a revolutionary new technology, enabling reliable and convenient diagnosis and management of bleeding disorders.

The fully-automated assay is available on the BCS® and BCS XP Systems, the Sysmex® CA-560, CA-1500, CA-7000, CS-2000i and 2100i Systems, enabling true von Willebrand factor (VWF) activity determinations for laboratories of all sizes.

New Technology Provides Stable, Robust, and Sensitive VWF Determination

The INNOVANCE VWF Ac assay is a sensitive, reliable, and convenient test for direct determination of VWF activity. It employs an advanced new technology, allowing the assay to mimic the reaction in which VWF binds to glycoprotein Ib (GPIb), the major VWF receptor protein on platelets. Latex particles are coated with an antibody against GPIb, to which recombinant GPIb is added. The addition of patient plasma induces a VWF-dependent agglutination, which is detected turbidimetrically. Because the recombinant receptor protein includes two gain-of-function mutations, the assay does not require ristocetin.

The INNOVANCE VWF Ac assay makes it easy to perform comprehensive, highly accurate VWF testing, even in smaller labs.

• Detects qualitative and quantitative VWF defects
• Excellent reproducibility
• Liquid, ready-to-use reagent
• High lot-to-lot consistency
• Long reagent stability―4 weeks after opening
• Available on all Siemens’ automated hemostasis systems

Please contact your Siemens representative for more information.